Magadh Chronicle

Atopic Dermatitis Pipeline Insight and Clinical Trial Analysis | 100+ Companies and 100+ Drugs

 Breaking News
  • No posts were found

Atopic Dermatitis Pipeline Insight and Clinical Trial Analysis | 100+ Companies and 100+ Drugs

January 16
19:05 2023
Atopic Dermatitis Pipeline Insight and Clinical Trial Analysis | 100+ Companies and 100+ Drugs

DelveInsight’s, “Atopic Dermatitis Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis pipeline drug profiles, including Atopic Dermatitis clinical trial and nonclinical stage products. It also covers the Atopic Dermatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Atopic Dermatitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Atopic Dermatitis clinical trial studies, NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Atopic Dermatitis Pipeline Report

  • DelveInsight’s Atopic Dermatitis Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Atopic Dermatitis.
  • The leading Atopic Dermatitis Companies include Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
  • Promising Atopic Dermatitis pipeline therapies such as Baricitinib, Lebrikizumab, MEDI9929, and others.
  • The Atopic Dermatitis Companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis R&D. The Atopic Dermatitis pipeline therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma.

 

Explore more information on the latest breakthroughs in the Atopic Dermatitis treatment landscape of the report @ Atopic Dermatitis Pipeline Outlook

 

Recent Developmental Activities in the Atopic Dermatitis Treatment Landscape

  • LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.
  • BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.
  • Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

 

Atopic Dermatitis Overview

Atopic dermatitis, often referred to as eczema, is a chronic (long-lasting) disease that causes inflammation, redness, and irritation of the skin. It is a common condition that usually begins in childhood; however, anyone can get the disease. Atopic dermatitis is not contagious, so it cannot be spread from person to person. Atopic dermatitis causes the skin to become extremely itchy. Scratching leads to further redness, swelling, cracking, “weeping” clear fluid, crusting, and scaling. In most cases, there are periods of time when the disease is worse, called flares, followed by periods when the skin improves or clears up entirely, called remissions. Researchers do not know what causes atopic dermatitis, but they do know that genes, the immune system, and the environment play a role in the disease. Depending on the severity and location of the symptoms, living with atopic dermatitis can be hard. Treatment can help control symptoms. For many people, atopic dermatitis improves by adulthood, but for some, it can be a lifelong illness. The most common symptom of atopic dermatitis is itching, which can be severe.

 

Find the information related to the Atopic Dermatitis emerging therapies and companies @ Atopic Dermatitis Ongoing Clinical Trials Analysis

 

Atopic Dermatitis Emerging Drugs Profile

 

Amlitelimab: Kymab

Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

 

BX 005: BiomX

BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

 

LP 0145: LEO Pharma

LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

 

Atopic Dermatitis Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Atopic Dermatitis. The companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. Phase II include, LEO Pharma.

 

For further information, refer to the detailed Atopic Dermatitis Pipeline Report @ Atopic Dermatitis Treatment Landscape

 

Scope of the Atopic Dermatitis Pipeline Report

  • Coverage- Global
  • Atopic Dermatitis Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
  • Atopic Dermatitis pipeline therapies such as Baricitinib, Lebrikizumab, MEDI9929, and others.
  • Atopic Dermatitis Segmentation: Phases, Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Table of Content

  1. Introduction
  2. Atopic Dermatitis Executive Summary
  3. Atopic Dermatitis: Overview
  4. Atopic Dermatitis Pipeline Therapeutics
  5. Atopic Dermatitis Therapeutic Assessment
  6. Atopic Dermatitis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name : Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Amlitelimab: Kymab
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. Drug name : Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Atopic Dermatitis Key Companies
  21. Atopic Dermatitis Key Products
  22. Atopic Dermatitis- Unmet Needs
  23. Atopic Dermatitis- Market Drivers and Barriers
  24. Atopic Dermatitis- Future Perspectives and Conclusion
  25. Atopic Dermatitis Analyst Views
  26. Atopic Dermatitis Key Companies
  27. Appendix

 

Get to know more information related to the Atopic Dermatitis Pipeline Therapies and Companies @ Atopic Dermatitis Market Drivers and Barriers

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/